Archive | Biopharmaceuticals

Biotech Bull Market Under Pressure: Now Flat to Down in 2018…Rally 10/16!…Updates

buy Lyrica online in uk Update at 3:15p EDT10/23 looks like vicious selling is over as more green shows up in biotech mid-caps and market trending up near flat line. Biogen (BIIB) up slightly to $318+ after earnings. Update at 9:30a EDT 10/23 NASDAQ Futures Down 1.8%+…XBI breaks through support at $83.55, down 5% YTD and 17% off Sep 1 top. […]

Continue Reading 0

Biotech Momentum Lost Mired in Macro-Economic News Cycle: China, FED,Trade etc.

http://restginhisshadow.com/tag/complete/?http:/faithfulbloggers.co Biotech Momentum Lost Technical Breakdown: XBI Near April Bottom but XLV Looks Good Market Looking for Growth from Large Cap Earnings 10 year auction has tepid demand at Yield of 3.225%, NASDAQ at 7602 own 1.75% (Prices as of mid-day 1:30 p EDT) Biotech momentum losses were triggered by a reversal in investor psychology  because […]

Continue Reading 0

Rayno BioBeat #6: Biotech Sell-Off with Broad Market Concerns…Updates

cheap finasteride australia Update 10/5/18 Very Weak Technicals after Biotech Sell-Off NASDAQ market closed off the lows down 1.16% at 7788. Biotech ETF IBB down 1.15% just above 3 month support of 116. Biotech ETF XBI down 1.51% at 90.45 broke downtrend line and May support at 92. More losers again but a several winners: e.g. BLUE,CRSP,IONS,RHHBY. Our […]

Continue Reading 0

Mid-Cap Biopharma 2018 Stock Performance as of 9/30…Updates

Update-10/1 Rally Fades Early Today…NASDAQ Moves to Red An early rally faded quickly today after an initial spike from new “NAFTA” deal. Biotech ETFs were red IBB down 0.63%  and XBI down 1.34%. Mid-Cap biopharmas were mainly red with CAR-T and gene editing stocks hit hard: BLUE CRSP EDIT GWPH NTLA . Will provide news […]

Continue Reading 0

Biotech Bounces to Trend Line-Clinical News Lifts Stocks…Update ALXN, TSRO

Update 9/26: FED Rate Hike Curbs Traders but Biotech Rolls On The market dipped slightly then went red about 3:30P EDT resulting in a 0.4% loss for the Dow. Main rates will rise to the 2 to 2.25% level with more rate hikes in the future. During Trump’s Press Conference today he said he does not […]

Continue Reading 0

Biotechs Bounce Back, Dow and S&P Hit New Highs

Biotechs Bounce Back: Up From September Lows-Markets Surge Ahead XBI Up 1.66% to $97.16 up from 3 month tech support of $95;IBB up 1.39%. Broad  rally brings Dow up 1%, S&P up 0.81% to fresh highs-strong 4 mo. trend line. Sector Winners: Tech (XLK) up 1.18%, Materials (XLB) up 1.08%, Healthcare (XLV) new high up […]

Continue Reading 0

Biotech Weakens Further: September Down 5% -Updates ABBV GWPH TSRO

Update 9/19 : Lightened up on Abbvie (ABBV) in low 90s with news of CA lawsuit on Humira kickbacks. Amgen (AMGN) hits 52 week high in $204 range, strong hold up 14.9% YTD. GW Pharmaceuticals (GWPH) rallies 6.61% to $159 for second day on cannabis trading frenzy; up 18.7% YTD with market cap $4.5B vs […]

Continue Reading 0

Rayno Biopharma Portfolio Movers: AMGN TSRO…Updates

9/16 The Week That Was: September Trending Down for Biotech NASDAQ-100 Holding (QQQ) at 184 up 1.7% last week. Large caps all weak on Friday; key will be Q3 earnings. FBT, IBB and XBI flat for the week; off highs reached 8/31/18. Mid-caps more mixed with strength in ICPT LGND NBIX NVCR RARE SGEN Healthcare […]

Continue Reading 0

Biotech Weakness but why Large Caps?…Updates

Update: 10:10a Tesaro (TSRO) Soars 15% to $38, short covering or bargain hunters? News item: expansion of Zejula Combo Trial in NSCLC ========= Biotech Weakness in Large Caps Mid-Caps Have Continued Strength The overall market recovered from an early sell-off but there was pronounced biotech weakness as well as in healthcare stocks one of the […]

Continue Reading 0

Biotechs Surge in August Best in Years: New Highs Hit for 2018…Updates

9/4/18 Biotech Weakness -Profit Taking or Caution for September Swoon? 1 PM EDT FBT down 1.38%, IBB down 1.55%, XBI down 0.73% Biotech stocks were extremely weak as of mid-day trading. Large caps were unusually weak given that they should be less volatile: CELG down 3.55%, BIIB down 3.06%, ALXN down 2.66%, GILD down 2.55%, […]

Continue Reading 0